# US Diverticular Disease Market > US Diverticular Disease Market Research Report By Type (Diverticulosis, Diverticulitis), By Treatment (Medication, Supportive Care, Surgery), By Diagnosis (CT Scan, Ultrasound, Urine Test, Blood Test) and By End User (Hospitals, Specialty Centers) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.37% - **2024:** $ 348.65 Million - **2025:** $ 377.84 Million - **2035:** $ 844.07 Million - **Key Players:** AbbVie Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Merck & Co., Inc. (US), Pfizer Inc. (US), Amgen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (JP) **Report ID:** MRFR/Pharma/15195-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-diverticular-disease-market-16723 --- ## Market Summary ## **US Diverticular Disease Market Overview** As per MRFR analysis, the US Diverticular Disease Market Size was estimated at 393.39 (USD Million) in 2023. The US Diverticular Disease Market Industry is expected to grow from 421.34(USD Million) in 2024 to 1,040.3 (USD Million) by 2035. The US Diverticular Disease Market CAGR (growth rate) is expected to be around 8.564% during the forecast period (2025 - 2035). ### **Key US Diverticular Disease Market Trends Highlighted** The US Diverticular Disease Market is witnessing significant trends driven by the increasing prevalence of diverticular diseases among the aging population. With over 60% of Americans over the age of 60 experiencing some form of diverticular disease, the demand for better treatment options and dietary management strategies is growing. This rise in cases is also prompting a heightened awareness of digestive health, thereby driving healthcare providers to develop tailored therapies and nutritional products that address the needs of affected individuals. Advanced treatments, including minimally invasive surgical procedures and novel pharmacological therapies, are emerging as key market drivers, enhancing patient outcomes and reducing recovery times. In recent times, there is a notable shift towards preventive healthcare. More healthcare practitioners in the US are encouraging dietary changes and preventive screenings, which presents an opportunity for companies to develop products like fiber supplements, probiotics, and educational resources that focus on gut health. Additionally, digital health solutions, including mobile applications that monitor and guide patients in dietary habits, are gaining traction. Research and development in the US are also directing attention towards understanding the microbiome's role in diverticular disease, opening avenues for innovative treatments that could cater specifically to the underlying causes rather than just managing symptoms. The introduction of health insurance policies that cover preventive measures and treatments for diverticular disease further enhances the market landscape, promoting early diagnosis and effective management. Overall, these trends reflect a proactive shift in addressing diverticular disease within the US, emphasizing a combination of prevention, early intervention, and advanced treatment options. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Diverticular Disease Market Drivers** ### **Increasing Prevalence of Diverticular Disease** The elevation in the prevalence of diverticular disease in the United States has been a significant driver for the US Diverticular Disease Market Industry. According to the Centers for Disease Control and Prevention (CDC), about 250,000 individuals are hospitalized each year due to diverticulitis, and it affects roughly 50% of adults over age 60. As the aging population in the U.S. continues to grow, with projections showing that by 2030, approximately 20% of the population will be over the age of 65, the number of individuals potentially suffering from diverticular disease is expected to rise. The National Institute of Diabetes and Digestive and Kidney Diseases has pointed out that the prevalence of this disease correlates directly with the aging demographic, creating an expanding market for treatment options and interventions. This rise emphasizes the need for increased healthcare resources devoted to the US Diverticular Disease Market. ### **Advancements in Medical Technologies and Surgical Procedures** The ongoing advancements in medical technologies and surgical procedures related to diverticular disease treatment provide a robust foundation for the growth of the US Diverticular Disease Market Industry. Innovative minimally invasive surgical techniques and improved imaging technologies have transformed how diverticular disease is diagnosed and treated. According to the American College of Surgeons, laparoscopic procedures have decreased recovery times and hospital stays, making surgical interventions more appealing for patients. Research indicates that the adoption of such minimally invasive technologies has grown by over 50% in the last five years, which is driving demand for targeted treatment options. This technological evolution signifies not only an improvement in patient outcomes but also a surge in healthcare expenditure toward these advanced treatments, further bolstering the US Diverticular Disease Market. ### **Rising Awareness and Education on Digestive Health** There has been a significant increase in awareness and education surrounding digestive health in the United States, which serves as a key driver for the US Diverticular Disease Market Industry. Campaigns led by organizations like the American Gastroenterological Association have been particularly effective in informing the public about the risks, symptoms, and treatments associated with diverticular disease. A survey conducted by the National Institute of Health revealed that educational efforts have increased awareness among patients and healthcare providers, leading to a 25% growth in early diagnosis of diverticular disease over the past three years. This heightened awareness drives more individuals to seek medical advice and treatment, supporting an expanding US Diverticular Disease Market. ### **Increased Healthcare Expenditure for Digestive Disorders** The rising healthcare expenditure in the United States is another major driver influencing the growth of the US Diverticular Disease Market Industry. The U.S. Department of Health and Human Services has reported that total healthcare spending is expected to reach approximately USD 6 trillion by 2027, fueled by a focus on treating chronic conditions including diverticular disease. This significant investment reflects a broader trend where hospitals and clinics are prioritizing better gastrointestinal care. The increase in healthcare spending allows for research and development into more effective treatments and medications, addressing the specific needs of diverticular disease patients. Consequently, this investment in healthcare infrastructure fundamentally supports the expansion and accessibility of the US Diverticular Disease Market. ## **US Diverticular Disease Market Segment Insights** ### **Diverticular Disease Market Type Insights** The US [Diverticular Disease Market](../../../reports/diverticular-disease-market-5694) is a significant segment within the broader healthcare landscape, particularly focusing on conditions such as Diverticulosis and Diverticulitis. Diverticulosis is characterized by the formation of pouches in the colonic wall, which, while often asymptomatic, can lead to complications if not managed properly. This condition is prevalent among the aging population and is believed to affect a considerable percentage of adults over 60 years old, making it a critical area for healthcare attention. On the other hand, Diverticulitis occurs when these pouches become inflamed or infected, leading to symptoms such as abdominal pain, fever, and changes in bowel habits. This often necessitates medical treatment and can sometimes require surgery. The increasing incidence of diverticular disease in the US, attributed to lifestyle factors such as diet and sedentary behavior, has driven a surge in demand for comprehensive treatment options and preventative measures. The US Diverticular Disease Market segmentation highlights the importance of understanding both these conditions, as they often coexist but require different management strategies. Diverticulosis management focuses significantly on dietary modifications and lifestyle changes, aiming to prevent progression to diverticulitis, which may involve more advanced medical interventions. The evolution in treatment protocols and increased awareness among healthcare providers and patients are key driving factors contributing to market growth. Healthcare providers are increasingly recognizing the need for patient education regarding the management of these diseases, which in turn influences treatment outcomes and reduces healthcare costs over time. Additionally, advancements in diagnostic technologies and a better understanding of risk factors are creating opportunities for early detection and intervention, thus improving patient care. As the US population continues to age, the implications of diverticular disease and its treatments will remain a pertinent focus for the healthcare industry. The overall market dynamics will be influenced by a mix of demographic changes, evolving dietary habits, and an increasing emphasis on preventive healthcare measures. With these insights, stakeholders in the US Diverticular Disease Market will have to strategize effectively to address the growing needs associated with Diverticulosis and Diverticulitis. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Diverticular Disease Market Treatment Insights** The Treatment segment of the US Diverticular Disease Market is a crucial component, focusing on various approaches to manage and alleviate symptoms associated with the condition. This segment includes Medication, Supportive Care, and Surgery, each contributing uniquely to addressing patient needs. Medication represents a primary response to manage acute symptoms and prevent disease progression, reflecting the trends toward pharmacological advances and improved patient adherence. Supportive Care plays a pivotal role in enhancing patients' quality of life, encompassing dietary management and counseling, tailored to individuals' conditions. Surgery, although considered when complications arise, remains significant for those with severe or recurrent cases, emphasizing the need for surgical interventions in managing advanced diverticular disease. As the population ages in the US, leading to increased incidences of diverticular disease, the Treatment segment is projected to grow, driven by evolving clinical guidelines and an uptick in healthcare expenditure. The growing focus on individualized patient treatment plans represents an opportunity for advanced therapeutic approaches, aligning with the increasing demand for specialized care in chronic conditions like diverticular disease. The US Diverticular Disease Market Statistics indicate that with advancements in medical technology and treatment strategies, this segment will continue to be a focal point for healthcare providers and patients alike. ### **Diverticular Disease Market Diagnosis Insights** The Diagnosis segment of the US Diverticular Disease Market plays a critical role in effective disease management, enabling early detection and treatment. Within this segment, diverse diagnostic methods are employed to assess diverticular disease, including CT Scans, Ultrasounds, Urine Tests, and Blood Tests. CT Scans are particularly significant, offering high-resolution images that assist in identifying complications and guiding treatment options. Ultrasounds are non-invasive and can be particularly useful in assessing the presence of diverticula without exposing patients to radiation. Urine and Blood Tests serve as essential adjuncts, helping to identify associated infections or complications. The collective advancement of these diagnostic tools strengthens the accuracy and efficiency of diagnosis, enhancing patient outcomes. This robust approach to diagnosis not only aligns with the growing demand for health services in the US but also reflects trends towards minimally invasive procedures and quicker diagnostic turnaround times, driven by technological innovations and increased healthcare awareness in the population. The US government has recognized the notable rise in diverticular disease incidences, further emphasizing the importance of precise diagnostics to facilitate effective healthcare strategies. Overall, the Diagnosis segment holds significant value in shaping the landscape of diverticular disease management in the US. ### **Diverticular Disease Market End User Insights** The US Diverticular Disease Market demonstrates significant engagement from various End Users, notably Hospitals and Specialty Centers. Hospitals play a crucial role as they cater to a large population seeking treatment for diverticular disease, often providing advanced diagnostic facilities and comprehensive care. They possess the necessary infrastructure and skilled staff to manage a diverse range of complications associated with this condition. On the other hand, Specialty Centers offer focused treatment plans and personalized care, emphasizing minimally invasive procedures and innovative therapies, attracting patients looking for specialized attention. This sector’s growth is driven by factors such as the increasing prevalence of diverticular disease in the aging population and the rising awareness of effective treatment options. Additionally, advancements in diagnostic techniques and surgical treatments present opportunities for further market expansion. The interplay between these End Users reflects a growing recognition of the importance of a multifaceted approach in managing diverticular disease, contributing to improved patient outcomes and overall market growth. The segmentation in the US Diverticular Disease Market points to a dynamic landscape, shaping how care is delivered and optimized for patient needs. ## **US Diverticular Disease Market Key Players and Competitive Insights** The US Diverticular Disease Market is characterized by a competitive landscape shaped by a multitude of factors including the increasing prevalence of diverticulitis and the growing awareness of gastrointestinal health. As the healthcare ecosystem continues to evolve with advancements in therapeutic options, the competitive insights reveal a market that is not only addressing existing treatment gaps but also striving for innovative solutions to meet patient needs. The players in this market are leveraging their strengths to enhance patient outcomes while navigating the complexities of regulatory frameworks and market demands. A deeper understanding of competitive strategies, product offerings, and market positioning is essential for stakeholders looking to thrive in this dynamic environment. Merck and Co has established a significant presence in the US Diverticular Disease Market through its dedication to research and development aimed at enhancing gastrointestinal health. The company has cultivated strong relationships with healthcare providers and stakeholders, facilitating a deeper understanding of diverticular disease management. Merck and Co's extensive portfolio includes key therapies that focus on reducing the recurrence of diverticulitis, and its ability to navigate complex regulatory pathways has cemented its reputation as a trusted name in the field. The company’s strong emphasis on clinical evidence and patient-centered approaches further bolster its market position, allowing for a robust engagement with both healthcare professionals and patients alike. Bristol Myers Squibb has emerged as a formidable player in the US Diverticular Disease Market, driven by its innovative therapeutic offerings that address both the acute and chronic manifestations of diverticular disease. With a focus on enhancing treatment paradigms, Bristol Myers Squibb has developed a range of key products aimed at improving gastrointestinal health. The company's commitment to advancing research in this area has been bolstered by strategic mergers and acquisitions that have expanded its capabilities and market reach. This integration of new technologies and therapeutic approaches has reinforced Bristol Myers Squibb's position within the market, enabling it to effectively address patient needs while adapting to evolving industry trends. The combination of an established market presence and a strong pipeline of potential therapies continues to strengthen Bristol Myers Squibb's competitive edge, allowing it to remain a significant contributor to advancements in diverticular disease management within the US. ### **Key Companies in the US Diverticular Disease Market Include** ## **US Diverticular Disease Market Industry Developments** Recent developments in the US Diverticular Disease Market have been shaped by significant advancements and strategic movements by key players such as Merck and Co., Bristol Myers Squibb, and Takeda Pharmaceuticals. The market is experiencing a growth surge reflecting increased awareness of diverticular disease and the rising prevalence of gastrointestinal disorders among the aging population. In September 2023, Gilead Sciences announced a focused initiative on digestive diseases that aligns with their broader pipeline, including potential therapies for diverticular disease. Meanwhile, Bristol Myers Squibb concluded its acquisition of Celgene in November 2019, enhancing its portfolio in gastrointestinal therapeutics. Merger and acquisition activities continue to reshape the competitive landscape, as companies like Novartis and Pfizer explore collaborations to strengthen their product offerings. Additionally, AstraZeneca's commitment to Research and Development has also contributed to innovations in the market. Recent data from the CDC reflects rising treatment demand, leading to increased investments and expansions among the aforementioned companies, creating a dynamic environment for new technologies and treatments in diverticular disease management, with continuous updates on regulatory approvals further propelling market interest. ## **US Diverticular Disease Market Segmentation Insights** ### **Diverticular Disease Market Type Outlook** ### **Diverticular Disease Market Treatment Outlook** ### **Diverticular Disease Market Diagnosis Outlook** ### **Diverticular Disease Market End User Outlook** ## Market Drivers ### Rising Healthcare Expenditure The diverticular disease market is poised for growth due to rising healthcare expenditure in the US. Increased spending on healthcare services, including diagnostics and treatments for diverticular disease, reflects a broader trend towards prioritizing health and wellness. According to recent reports, healthcare spending in the US is projected to reach approximately $6 trillion by 2027, which may lead to enhanced access to medical care for patients with diverticular disease. This financial commitment from both public and private sectors could facilitate the development of new therapies and improve patient access to existing treatments. As healthcare systems invest in advanced technologies and treatment options, the diverticular disease market is likely to benefit from increased funding and resources. ### Advancements in Treatment Modalities Innovations in treatment modalities are significantly impacting the diverticular disease market. Recent developments in minimally invasive surgical techniques and pharmacological therapies have improved patient outcomes and reduced recovery times. For instance, laparoscopic surgery has become a preferred option for complicated diverticular disease cases, leading to shorter hospital stays and lower complication rates. Additionally, the introduction of new medications aimed at managing symptoms and preventing complications is likely to enhance treatment options available to patients. The market is projected to grow as these advancements become more widely adopted in clinical practice. As healthcare providers increasingly embrace these innovative approaches, the diverticular disease market is expected to expand, driven by improved patient satisfaction and outcomes. ### Increased Focus on Dietary Management Dietary management plays a crucial role in the diverticular disease market, as healthcare professionals emphasize the importance of nutrition in preventing and managing the condition. A high-fiber diet is often recommended to reduce the risk of diverticulitis and improve overall gut health. The growing awareness of the link between diet and diverticular disease is likely to drive demand for dietary supplements and functional foods designed to support digestive health. Market data suggests that the functional food sector is experiencing significant growth, with consumers increasingly seeking products that promote gut health. This trend indicates a potential expansion of the diverticular disease market, as more individuals adopt dietary strategies to manage their condition and prevent complications. ### Growing Prevalence of Diverticular Disease The diverticular disease market is experiencing growth due to the increasing prevalence of the condition among the population. Studies indicate that approximately 50% of individuals aged 60 and older in the US may develop diverticulosis, a precursor to diverticular disease. This rising incidence is likely to drive demand for diagnostic and therapeutic options, thereby expanding the market. Furthermore, the healthcare system's focus on preventive care and early intervention may lead to increased screening and awareness, contributing to market growth. As more individuals are diagnosed, the need for effective treatment options, including dietary management and surgical interventions, becomes paramount. This trend suggests a robust future for the diverticular disease market, as healthcare providers seek to address the needs of an aging population with a higher risk of developing this condition. ### Growing Research and Development Initiatives The diverticular disease market is being influenced by a surge in research and development initiatives aimed at understanding the condition better and discovering new treatment options. Academic institutions and pharmaceutical companies are increasingly focusing on clinical trials to evaluate the efficacy of novel therapies and interventions. This heightened research activity is expected to lead to the introduction of innovative products in the market, addressing unmet medical needs. Furthermore, collaboration between research entities and healthcare providers may enhance the translation of findings into clinical practice, ultimately benefiting patients. As the body of knowledge surrounding diverticular disease expands, the market is likely to see a rise in effective treatment options, contributing to its overall growth. ## Future Outlook The [Diverticular Disease Market](https://www.marketresearchfuture.com/reports/diverticular-disease-market-5694) is projected to grow at an 8.37% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in innovative dietary supplements targeting gut health - Expansion of minimally invasive surgical techniques for diverticular disease By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Type: Diverticulosis (Largest) vs. Diverticulitis (Fastest-Growing) The US diverticular disease market is primarily segmented into three types: diverticulosis, diverticular bleeding, and diverticulitis. Diverticulosis holds the largest market share due to its prevalence among the aging population and is often asymptomatic, leading to increased diagnosis rates. In contrast, diverticular bleeding and diverticulitis also represent significant segments but have smaller shares. While diverticular bleeding tends to have sporadic occurrences, diverticulitis is increasingly recognized as a critical condition that requires timely intervention. Growth trends in this segment are influenced by several factors, including rising awareness of diverticular disease and advancements in diagnostic technologies. Diverticulitis is emerging as the fastest-growing segment driven by increased incidence rates. Treatment options are expanding, with more emphasis on dietary modifications and surgical interventions, contributing to market growth. Additionally, increasing healthcare expenditure and a greater focus on gastrointestinal health are propelling this segment further. Diverticulosis: Dominant vs. Diverticulitis: Emerging Diverticulosis is characterized as the dominant segment in the US diverticular disease market, primarily due to its high prevalence and low symptomatology. It often goes unnoticed until complications arise, ensuring a steady patient base for healthcare providers. On the other hand, diverticulitis, classified as an emerging segment, presents notable growth potential as it demands more aggressive treatment. The recognition of diverticulitis is growing amongst healthcare professionals as it can lead to severe complications if untreated. This connection to complications fosters heightened surveillance and management practices, bolstering its market position. As aging populations increase and lifestyle factors contribute to diverticulitis cases, the demand for effective diagnostic and therapeutic options will likely rise. ### By Treatment: Medications (Largest) vs. Surgery (Fastest-Growing) In the treatment segment of the US diverticular disease market, Medications hold the largest market share, driven by their widespread prescription and usage. The segment includes various classes of drugs, such as antibiotics and dietary supplements, which cater to diverse patient needs. In contrast, Surgery has been identified as the fastest-growing category, reflecting a shift towards surgical interventions as the disease progresses, emphasizing the need for effective care options. Growth trends indicate a steady increase in demand for both Medications and Surgical procedures as awareness of diverticular disease rises. Factors like the aging population and increasing incidence of diverticular complications contribute to the growth. Additionally, advancements in surgical techniques and the development of new medications foster innovation in treatment protocols, ensuring optimal patient outcomes. Medications (Dominant) vs. Surgery (Emerging) Medications dominate the treatment segment, encompassing antibiotics, dietary supplements, and supportive care products, reflecting their critical role in managing diverticular disease. The availability of prescription and over-the-counter options enhances accessibility, leading to widespread adoption among patients. Conversely, the Surgery segment is emerging, characterized by innovative techniques such as laparoscopic procedures. As healthcare providers focus on minimizing recovery times and improving efficacy, the surgical options gain traction among patients requiring intervention. This dynamic interplay between Medications and Surgery illustrates the evolving landscape of treatment in the US diverticular disease market. ### By Diagnosis: CT scan (Largest) vs. Ultrasound (Fastest-Growing) In the US diverticular disease market, segment values such as Barium X-ray, CT scan, Liver function test, Blood test, Urine test, and Ultrasound together present a diverse landscape for diagnostic methods. Among these, the CT scan holds the largest market share due to its comprehensive imaging capabilities and higher accuracy compared to traditional methods. Other diagnostic tests like Barium X-ray and Liver function tests follow, but they lack the same breadth of adoption that the CT scan enjoys. The growth trends in this segment are influenced by various factors such as advancements in imaging technology and an increasing prevalence of diverticular disease among the population. The ultrasound has emerged as the fastest-growing diagnostic method within this segment, driven by its non-invasive nature and cost-effectiveness, making it a preferred choice in many clinical settings. Other tests, while still significant, are seeing slower growth rates as healthcare providers shift their focus toward newer technologies. CT scan (Dominant) vs. Ultrasound (Emerging) The CT scan remains the dominant diagnostic tool in the US diverticular disease market, known for providing quick and accurate images, which help in precise diagnoses. Its extensive use in emergency and routine cases has solidified its market position. On the other hand, Ultrasound is emerging as a key player, favored for its non-invasive approach and safety profile, especially in outpatient settings. The reduced cost and increased accessibility of ultrasound equipment allow for a broader reach in prescribing this diagnostic method, particularly amidst healthcare system reforms emphasizing value-based care. Together, these tools represent two sides of the diagnostic spectrum, balancing the need for accuracy with cost efficiency. ### By End User: Hospitals (Largest) vs. Specialty centers (Fastest-Growing) The market share distribution among the end user segments reveals that hospitals currently hold a significant portion, making them the largest segment in the US diverticular disease market. Specialty centers are also emerging, demonstrating strong growth potential as they provide tailored services that meet specific patient needs. Research centers, while critical for advancing treatment options, maintain a smaller share compared to these two segments. Growth trends in this segment are primarily driven by the increasing prevalence of diverticular disease and the rising demand for specialized care. Hospitals are expanding their facilities and resources to accommodate more patients, while specialty centers are rapidly evolving to deliver innovative treatments. Research centers play an essential role in developing new therapies, thus contributing to overall market advancements and attracting investments in specialized medical practices. Hospitals (Dominant) vs. Specialty centers (Emerging) Hospitals dominate the end user segment due to their extensive infrastructure and ability to provide comprehensive care for diverticular disease patients. They offer a wide range of services, including surgical interventions and follow-up care, making them the preferred choice for many individuals. On the other hand, specialty centers are emerging as key players in the market by focusing on niche treatments and personalized patient experiences. Their growth is fueled by an increase in awareness and a shift towards more specialized healthcare solutions. Both segments are valuable, with hospitals maintaining dominance while specialty centers cater to the growing demand for personalized care. ## Competitive Benchmarking The diverticular disease market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AbbVie Inc (US), Bristol-Myers Squibb Company (US), and Johnson & Johnson (US) are actively engaged in enhancing their product portfolios and expanding their market reach. AbbVie Inc (US) has positioned itself as a leader in the development of biologics, focusing on advanced therapies that address the underlying causes of diverticular disease. Meanwhile, Bristol-Myers Squibb Company (US) emphasizes its commitment to research and development, particularly in immunotherapy, which may offer new avenues for treatment. Johnson & Johnson (US) continues to leverage its extensive global footprint to enhance access to its innovative solutions, thereby shaping the competitive dynamics of the market.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market appears moderately fragmented, with a mix of established players and emerging biotech firms. This structure allows for a diverse range of treatment options, although the influence of major companies remains substantial. Their collective strategies not only enhance their competitive positioning but also contribute to a more robust market environment. In October AbbVie Inc (US) announced a strategic partnership with a leading research institution to accelerate the development of a novel biologic aimed at treating diverticular disease. This collaboration is expected to enhance AbbVie’s research capabilities and expedite the clinical trial process, potentially leading to a first-in-class therapy. The strategic importance of this partnership lies in its potential to solidify AbbVie’s market leadership and expand its therapeutic offerings in a competitive landscape. In September Bristol-Myers Squibb Company (US) launched a new clinical trial for an innovative immunotherapy treatment targeting diverticular disease. This initiative underscores the company’s focus on harnessing cutting-edge science to develop effective therapies. The trial's outcomes could significantly influence treatment paradigms and position Bristol-Myers Squibb as a frontrunner in the market, particularly if the therapy demonstrates superior efficacy. In August Johnson & Johnson (US) expanded its manufacturing capabilities in the US to enhance the production of its diverticular disease treatments. This move is indicative of the company’s commitment to ensuring supply chain reliability and meeting growing patient demand. By bolstering its manufacturing infrastructure, Johnson & Johnson not only improves its operational efficiency but also strengthens its competitive edge in a rapidly evolving market. As of November the diverticular disease market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain resilience. This shift may redefine how companies approach market entry and product development, ultimately benefiting patients through enhanced treatment options. ## Recent News & Developments Recent developments in the US Diverticular Disease Market have been shaped by significant advancements and strategic movements by key players such as Merck and Co., Bristol Myers Squibb, and Takeda Pharmaceuticals. The market is experiencing a growth surge reflecting increased awareness of diverticular disease and the rising prevalence of gastrointestinal disorders among the aging population. In September 2023, Gilead Sciences announced a focused initiative on digestive diseases that aligns with their broader pipeline, including potential therapies for diverticular disease. Meanwhile, Bristol Myers Squibb concluded its acquisition of Celgene in November 2019, enhancing its portfolio in gastrointestinal therapeutics. Merger and acquisition activities continue to reshape the competitive landscape, as companies like Novartis and Pfizer explore collaborations to strengthen their product offerings. Additionally, AstraZeneca's commitment to Research and Development has also contributed to innovations in the market. Recent data from the CDC reflects rising treatment demand, leading to increased investments and expansions among the aforementioned companies, creating a dynamic environment for new technologies and treatments in diverticular disease management, with continuous updates on regulatory approvals further propelling market interest. ## Report Scope | MARKET SIZE 2024 | 348.65(USD Million) | | --- | --- | | MARKET SIZE 2025 | 377.84(USD Million) | | MARKET SIZE 2035 | 844.07(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.37% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AbbVie Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Merck & Co., Inc. (US), Pfizer Inc. (US), Amgen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (JP) | | Segments Covered | Type, Treatment, Diagnosis, End User | | Key Market Opportunities | Advancements in minimally invasive surgical techniques enhance treatment options in the diverticular disease market. | | Key Market Dynamics | Rising demand for minimally invasive treatments drives innovation in the diverticular disease market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current market valuation of the US diverticular disease market?** A: The market valuation was $348.65 Million in 2024. **Q: What is the projected market size for the US diverticular disease market by 2035?** A: The projected market size is $844.07 Million by 2035. **Q: What is the expected CAGR for the US diverticular disease market during the forecast period 2025 - 2035?** A: The expected CAGR is 8.37% during the forecast period 2025 - 2035. **Q: Which companies are the key players in the US diverticular disease market?** A: Key players include AbbVie Inc, Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Amgen Inc., Gilead Sciences, Inc., and Takeda Pharmaceutical Company Limited. **Q: What are the main types of diverticular disease and their market valuations?** A: Diverticulosis, diverticular bleeding, and diverticulitis had valuations of $139.46 Million, $69.73 Million, and $139.46 Million respectively in 2024. **Q: What treatment options are available for diverticular disease and their market values?** A: Treatment options include medications valued at $50.0 Million, surgery at $80.0 Million, and supportive care at $30.0 Million in 2024. **Q: What diagnostic methods are used for diverticular disease and their market valuations?** A: Diagnostic methods include CT scans valued at $100.0 Million and blood tests at $50.0 Million in 2024. **Q: What are the end-user segments in the US diverticular disease market?** A: End-user segments include hospitals valued at $200.0 Million and specialty centers at $50.0 Million in 2024. **Q: How does the market for diverticular disease appear to be evolving?** A: The market appears to be growing, with a projected increase to $844.07 Million by 2035. **Q: What factors might influence the growth of the US diverticular disease market?** A: Factors influencing growth may include advancements in treatment options and increasing awareness of diverticular disease. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-diverticular-disease-market-16723*